Publications by authors named "Petar M Seferovic"

Takotsubo syndrome (TTS) still remains as an enigmatic phenomenon. In particular, long-term challenges (including clinical recurrence and persistent symptoms) and specific entities in the setting of TTS have been the evolving areas of interest. On the other hand, a significant gap still exists regarding the proper risk-stratification of this phenomenon in the short and long terms.

View Article and Find Full Text PDF

In the recent years, there has been a burgeoning interest in Takotsubo syndrome (TTS), which is renowned as a specific form of reversible myocardial dysfunction. Despite the extensive literature available on TTS, clinicians still face several practical challenges associated with the diagnosis and management of this phenomenon. This potentially results in the underdiagnosis and improper management of TTS in clinical practice.

View Article and Find Full Text PDF

Aims: We analysed baseline characteristics and guideline-directed medical therapy (GDMT) use and decisions in the European Society of Cardiology (ESC) Heart Failure (HF) III Registry.

Methods And Results: Between 1 November 2018 and 31 December 2020, 10 162 patients with acute HF (AHF, 39%, age 70 [62-79], 36% women) or outpatient visit for HF (61%, age 66 [58-75], 33% women), with HF with reduced (HFrEF, 57%), mildly reduced (HFmrEF, 17%) or preserved (HFpEF, 26%) ejection fraction were enrolled from 220 centres in 41 European or ESC-affiliated countries. With AHF, 97% were hospitalized, 2.

View Article and Find Full Text PDF
Article Synopsis
  • Peripartum cardiomyopathy (PPCM) is a serious heart condition affecting mothers, and this study investigates the use of bromocriptine, a potential treatment alongside standard care, to see if it improves maternal outcomes.
  • The study analyzed data from the EORP PPCM registry, comparing outcomes of 85 patients treated with bromocriptine to 409 patients receiving standard treatment, revealing that bromocriptine was linked to better maternal health outcomes.
  • Results showed a significant reduction in adverse outcomes for the bromocriptine group (22% had complications) compared to the standard care group (33%), suggesting that bromocriptine may be an effective option for treating PPCM.
View Article and Find Full Text PDF
Article Synopsis
  • Heart transplantation (HTx) has been around for over 50 years, yet there's a lack of guidelines for post-transplant prevention and rehabilitation practices.
  • The statement emphasizes the need for tailored prevention and rehabilitation programs that consider both modifiable and non-modifiable factors to enhance the physical capacity and quality of life for HTx recipients.
  • It advocates for a multidisciplinary approach involving all members of the HTx team to support patients throughout their recovery journey, highlighting the importance of starting these programs early after transplantation.
View Article and Find Full Text PDF
Article Synopsis
  • The text highlights a lack of knowledge and guidelines on physical activity and lifestyle measures for heart transplantation (HTx) recipients, despite the procedure's long history.
  • It emphasizes the need for tailored prevention and rehabilitation strategies to enhance physical capacity, quality of life, and survival for these patients.
  • The statement calls for a multidisciplinary approach to care, starting early post-transplant and continuing throughout the patients' journey, as HTx recipients have unique rehabilitation needs compared to other heart-related patients.
View Article and Find Full Text PDF
Article Synopsis
  • Limited information exists on the physical activity and lifestyle measures for heart transplantation (HTx) recipients, despite the history of HTx spanning over 50 years without established guidelines for prevention and rehabilitation.
  • The scientific statement aims to highlight the significance of prevention and rehabilitation post-HTx and identify both modifiable and non-modifiable factors that can enhance physical capacity, quality of life, and survival for these patients.
  • A multidisciplinary approach is essential for developing tailored prevention and rehabilitation programs that begin early after HTx and continue throughout the patient's recovery journey.
View Article and Find Full Text PDF

Aim: Sacubitril/valsartan treatment reduces mortality and hospitalizations in heart failure with reduced ejection fraction but has limited application in hypertrophic cardiomyopathy (HCM). The aim of this study was to evaluate the effect of sacubitril/valsartan on peak oxygen consumption (VO) in patients with non-obstructive HCM.

Methods And Results: This is a phase II, randomized, open-label multicentre study that enrolled adult patients with symptomatic non-obstructive HCM (New York Heart Association class I-III) who were randomly assigned (2:1) to receive sacubitril/valsartan (target dose 97/103 mg) or control for 16 weeks.

View Article and Find Full Text PDF
Article Synopsis
  • Guideline-directed medical therapy (GDMT) is crucial for reducing illness and death in patients with heart failure and reduced ejection fraction (HFrEF), but it's not being used effectively in practice.
  • Barriers like clinical inertia and organizational issues often lead to delays in starting or optimizing recommended treatments.
  • The Heart Failure Association of the ESC highlights various strategies, such as improving heart failure care pathways, using digital tools, and increasing education for both patients and healthcare providers, to enhance the implementation of GDMT for better patient outcomes.
View Article and Find Full Text PDF

Background And Aims: Contemporary multicentre data on clinical and diagnostic spectrum and outcome in myocarditis are limited. Study aims were to describe baseline features, 1-year follow-up, and baseline predictors of outcome in clinically suspected or biopsy-proven myocarditis (2013 European Society of Cardiology criteria) in adult and paediatric patients from the EURObservational Research Programme Cardiomyopathy and Myocarditis Long-Term Registry.

Methods: Five hundred eighty-one (68.

View Article and Find Full Text PDF

In the primary care setting providers have more tools available than ever before to impact positively obesity, diabetes, and their complications, such as renal and cardiac diseases. It is important to recognise what is available for treatment taking into account diabetes heterogeneity. For those who develop type 2 diabetes (T2DM), effective treatments are available that for the first time have shown a benefit in reducing mortality and macrovascular complications, in addition to the well-established benefits of glucose control in reducing microvascular complications.

View Article and Find Full Text PDF

Aims: Natriuretic peptide (NP) uptake varies in Emergency Departments (EDs) across Europe. The 'Peptide for Life' (P4L) initiative, led by Heart Failure Association, aims to enhance NP utilization for early diagnosis of heart failure (HF). We tested the hypothesis that implementing an educational campaign in Western Balkan countries would significantly increase NP adoption rates in the ED.

View Article and Find Full Text PDF
Article Synopsis
  • The European Society of Cardiology Heart Failure III Registry aims to improve understanding of heart failure (HF) clinical features and outcomes, as current therapies aren't delivering satisfactory results.
  • Over 10,000 patients with various types of heart failure were studied across 220 centers in Europe from late 2018 to late 2020, collecting extensive data on their health, treatment decisions, and follow-ups.
  • The findings from this registry are expected to influence future heart failure care strategies, research, and health policies across Europe.
View Article and Find Full Text PDF

Cardiomyopathies are a significant contributor to cardiovascular morbidity and mortality, mainly due to the development of heart failure and increased risk of sudden cardiac death (SCD). Despite improvement in survival with contemporary treatment, SCD remains an important cause of mortality in cardiomyopathies. It occurs at a rate ranging between 0.

View Article and Find Full Text PDF

Cardiac tamponade is a medical emergency caused by the progressive accumulation of pericardial fluid (effusion), blood, pus or air in the pericardium, compressing the heart chambers and leading to haemodynamic compromise, circulatory shock, cardiac arrest and death. Pericardial diseases of any aetiology as well as complications of interventional and surgical procedures or chest trauma can cause cardiac tamponade. Tamponade can be precipitated in patients with pericardial effusion by dehydration or exposure to certain medications, particularly vasodilators or intravenous diuretics.

View Article and Find Full Text PDF

Cardiomyopathies represent significant contributors to cardiovascular morbidity and mortality. Over the past decades, a progress has occurred in characterization of the genetic background and major pathophysiological mechanisms, which has been incorporated into a more nuanced diagnostic approach and risk stratification. Furthermore, medications targeting core disease processes and/or their downstream adverse effects have been introduced for several cardiomyopathies.

View Article and Find Full Text PDF

Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (HF). In addition, they can have an important complementary role in the risk stratification of its prognosis. Since the development of angiotensin receptor neprilysin inhibitors (ARNIs), the use of natriuretic peptides as therapeutic agents has grown in importance.

View Article and Find Full Text PDF

Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (HF). In addition, they can have an important complementary role in the risk stratification of its prognosis. Since the development of angiotensin receptor-neprilysin inhibitors (ARNIs), the use of natriuretic peptides as therapeutic agents has grown in importance.

View Article and Find Full Text PDF